What is the recommended therapy for malaria?

Malaria Treatment

Artemether-lumefantrine (AL) is the first-line treatment for uncomplicated malaria, administered as 4 tablets at 0 hours, 4 tablets at 8 hours on day 1, then 4 tablets twice daily on days 2 and 3, and must be taken with fatty food to ensure adequate absorption and prevent treatment failure. 1, 2

Treatment Algorithm by Disease Severity

Uncomplicated Malaria

For uncomplicated P. falciparum malaria:

• First-line: Artemether-lumefantrine with cure rates of 96-100% 1
• Critical administration requirement: AL must be taken with fatty food or drink; failure to do so results in subtherapeutic drug levels and treatment failure 1, 3, 2
• Alternative first-line: Dihydroartemisinin-piperaquine (3 tablets daily for 3 days for 36-75 kg, or 4 tablets daily for >75 kg), taken on an empty stomach 1
• Second-line options: Atovaquone-proguanil (4 tablets daily for 3 days with fatty meal) when ACTs are contraindicated 1, 3

For chloroquine-sensitive regions (e.g., Haiti):

• Chloroquine remains an option: 1,500 mg total dose over 3 days (600 mg, 600 mg, 300 mg at 0,24,48 hours) 1, 4

For P. vivax, P. ovale, and P. malariae:

• Either ACT or chloroquine for initial treatment in chloroquine-sensitive regions 3, 5
• Mandatory follow-up: Primaquine 30 mg base daily for 14 days to eliminate liver hypnozoites and prevent relapse, but only after confirming G6PD status 3, 5
• Primaquine is more effective when taken concurrently with chloroquine 5

Severe Malaria

For severe P. falciparum malaria:

• First-line: Intravenous artesunate with monitoring of parasitemia every 12 hours until <1%, then every 24 hours until negative 1, 2, 4, 5
• Once parasitemia is <1% and patient can tolerate oral medications, complete treatment with a full course of oral ACT 1, 2
• Manage in high-dependency or intensive care environment with support for potential complications including acute respiratory distress syndrome, disseminated intravascular coagulation, acute kidney injury, and seizures 5

Special Populations

Pregnant Women

• Second and third trimesters: Artemether-lumefantrine with cure rates of 94.9-100% and no increased risk of adverse pregnancy outcomes 6, 1
• First trimester: AL can be used when other options are unavailable; quinine plus clindamycin is an alternative 6, 2
• Severe malaria in any trimester: Intravenous artesunate preferred over quinine 5
• Primaquine is absolutely contraindicated in pregnancy; use weekly chloroquine prophylaxis until delivery, then consider hypnozoite eradication 5

Children

• Artemether-lumefantrine or dihydroartemisinin-piperaquine as first-line treatment at weight-appropriate doses 5
• Children with severe malaria should receive empirical broad-spectrum antibiotics until bacterial infection is excluded 5
• Doxycycline should not be given to children under 12 years 5

Critical Monitoring and Safety Considerations

Post-treatment monitoring:

• Check hemoglobin on day 14 following intravenous artesunate treatment, as hemolysis occurs in 10-15% of patients 5
• Monitor for post-artemisinin delayed hemolysis (PADH) on days 7,14,21, and 28 after treatment 1, 3

Drug-specific warnings:

• Both AL and dihydroartemisinin-piperaquine can cause QTc prolongation; avoid in patients with baseline QT prolongation or those taking QT-prolonging medications 1, 3, 2
• Test for G6PD deficiency before administering primaquine, as it can cause life-threatening hemolysis, particularly in Asian populations with severe G6PD deficiency 3, 5

Common Pitfalls to Avoid

• Most common cause of treatment failure: Not ensuring fatty food intake with artemether-lumefantrine administration 1, 3, 2
• Delayed diagnosis: Malaria must be considered in any febrile patient with recent travel to endemic areas; delayed diagnosis of P. falciparum is associated with increased mortality 2, 4, 5
• Diagnostic errors: The diagnosis cannot be excluded until more than one blood specimen has been examined 5
• Mixed infections: Can involve P. falciparum with attendant risks of severe malaria; treat as P. falciparum 5
• Primaquine administration: Not testing for G6PD deficiency before primaquine can cause severe hemolysis 3, 5

Emerging Resistance Concerns

• Artemether-lumefantrine efficacy is declining in some regions of east Africa, with uncorrected adequate clinical and parasitological response rates as low as 51.8% in Uganda 7
• PfK13 mutations (Cys469Tyr and Ala675Val) are associated with delayed parasite clearance (median 4.2-4.9 hours vs 2.8 hours for wild-type) 7
• Consider regional resistance patterns when selecting ACT regimens 8